CAPLA trial: Catheter Ablation for persistent atrial fibrillation: A Multicentre randomised trial of Pulmonary vein antral isolation (PVAI) vs PVAI with posterior left atrial wall isolation (PWI).

Not Applicable

Completed

• Conditions: atrial fibrillation; Cardiovascular - Other cardiovascular diseases; Surgery - Surgical techniques

• Registration Number: ACTRN12616001436460
• Lead Sponsor: Alfred Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-10-14
• Study Completion: 2022-04-01
• Last Update Posted: 22 August 2022

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 338

Inclusion Criteria

Patients aged 18 to 80 yeasr old with symptomatic documented persistent AF who have trialled and failed to antiarrhythmic therapy

Exclusion Criteria

Paroxysmal AF. Patients with permanent or chronic persistent AF > 18months. AF secondary to reversible cause such as thyrotoxicosis or severe untreated sleep apnoea. Patients with contra indication to anticoagulation. Creatinine >200, End stage renal or hepatic failure. Severe valvular heart disease or cyanotic congenital heart disease.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Single procedure success rate (i.e No documented AF/AT/AFL >30 seconds) off antiarrhythmic drugs at 12 months. This specific outcome of recurrence of AF/AT/ AFL is evaluated in all patients. If they require the use of anti arrhythmic therapy after their procedure, it reflects potential recurrence, hence it is a primary outcome. Recurrence of atrial arrhythmia for >30 seconds is assessed by 7 day holter monitor, AliveCor rhythm monitoring system, implantable loop recorder or ECG[AF or atrial tachyvcardia recurrence over 12 months]